Table 5: Selected clinical trials using autologous tumor cells (ATCs).

ReferencePatientsImmunologic responseClinical response

[174]
recurrent GBM
Local skin reactionMedian survival: 46 weeks
[175]
GBM
Delayed-type hypersensitivity, increased memory T cells, increased CD8+ T cells in recurrent tumorsMedian progression free survival: 40 weeks, median survival 100 weeks
[176]
GBM
CR: 1, PR: 1, minor response: 2, median survival: 10.7 mo